Citations

Clear

151 citation(s) found for "Mathieu, D".

A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01
Borad, Mitesh J. , Busset, Michele Droz Dit , Javle, Milind , Shaib, Walid L. , Personeni, Nicola , Mody, Kabir , Bergamo, Francesca, Harris, William P., Damjanov, Nevena , Macarulla, Teresa , Brandi, Giovanni , Masi, Gianluca , Abou‐Alfa, Ghassan K. , Hálfdánarson, Þorvarður R. , Knox, Jennifer, Tam, Vincent C. , Bernat, Mathieu, Engelhardt, Marc , Friedmann, Silke, Häckl, Manuel, McKernan, Phil, Saulay, Mikael, Goff, Laura W. , Hollebecque, Antoine , Adeva, Jorge , Jeffry Evans, Thomas R. , Bridgewater, John , Foerster, Friedrich , Kendall, Stephan DiSean, Roth, Gaël , Cunningham, David, Vogel, Arndt , Niger, Monica , Mahipal, Amit , Mazzaferro, Vincenzo

Mayo Clinic

Hepatology | October 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001902 | PMID 42937546 Get It

Background & Aims: To evaluate safety and efficacy of FGFR1–3 kinase inhibitor derazantinib, in advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions or rearrangements ( FGFR2 F ), mutations ( FGFR2 M ), or amplifications ( FGFR2 A ), previously treated with chemotherapy. Approach & Results: Open-label, non-controlled Phase 2 trial. Patients with advanced iCCA, ≥1 prior chemotherapy, and FGFR2 F (Substudy 1) or FGFR2 M /FGFR A (Substudy 2), received once-daily oral derazantinib 300 mg until disease progression, unacceptable toxicity, consent withdrawal or investigator decision to stop. Efficacy was assessed by central radiology review using RECIST v1.1. Primary endpoints were objective response rate (ORR; Substudy 1) and 3-month progression-free survival (PFS3; Substudy 2). Other endpoints were PFS, ORR (Substudy 2), disease control rate (DCR), duration of response (DOR), and overall survival (OS). In Substudy 1, ORR and DCR were 22.3% (23/103 partial responses) and 75.7%, respectively; median (95% CI) PFS was 8.1 (5.5,8.3) months, DOR was 6.5 (4.6,9.2) months, and OS was 17.2 (12.5,22.4) months. In Substudy 2, PFS3 was 63% (27/43), ORR was 9.3% (3 partial, 1 complete response), DCR was 69.8%, and OS was 11.9 (8.4,15.9) months. There were no Grade 4 or 5 drug-related events. FGFR inhibitor class-specific toxicities included drug-related hyperphosphataemia (38%, Grade 3: 3%) and dry eye (36%). Nail disorders (10%, any grade or causality), stomatitis (5%), retinal events (5%), and palmar-plantar erythrodysesthesia (1%) were infrequent. Conclusions: In previously chemotherapy treated, FGFR-inhibitor-naïve patients with iCCA harboring FGFR2 fusions, mutations, or amplifications, derazantinib showed clinically meaningful efficacy with durable objective responses, and a manageable safety profile.
Targeted single-nucleus sequencing of 39,800 neurons reveals extensive low-frequency somatic variants
Bidhan, Vanshika , Wynants, Sarah , Vicente, Cristina T, Küçükali, Fahri , Broeck, Marleen Van den , Rooij, Jeroen GJ van, Mol, Merel O. , Kaat, Laura L Donker, Al-Sarraj, Safa, King, Andrew, Troakes, Claire , Schaeverbeke, Jolien, Thal, Dietmar Rudolf , Vandenberghe, Rik , Vandenbulcke, Mathieu , Nguyen, Aivi T. , Reichard, R. Ross , Kofler, Julia, Lopez, Oscar L, White, Charles L. , Boeve, Bradley F. , Graff-Radford, Neill R, Josephs, Keith A, Petersen, Ronald C, Ghayal, Nikhil B , Murray, Melissa E. , Dickson, Dennis W. , Swieten, John C van, Sleegers, Kristel , Seelaar, Harro , Coster, Wouter De , Rademakers, Rosa , Swings, Toon , Rooij, Jeroen van , Kaat, Laura Donker , Bódi, István , Proukakis, Christos , Schaeverbeke, Jolien , Kofler, Julia , Graff‐Radford, Neill R. , Swieten, John C. van , Mol, Merel O , Proukakis, Christos , Thal, Dietmar Rudolf , Vandenberghe, Rik , Nguyen, Aivi T , Reichard, R Ross , White, Charles L , Boeve, Brad , Murray, Melissa E , Dickson, Dennis W , Seelaar, Harro , De Coster, Wouter , Rademakers, Rosa

Mayo Clinic

No container title available | September 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.21.753260 | PMID 42817963 Get It

Abstract Recent evidence implicates somatic mutations in disease-associated genes across multiple neurodegenerative disorders, including the identification of two somatic TARDBP variants as a putative cause of frontotemporal lobar degeneration with TDP-43 pathology type C (FTLD-TDP type C). However, these findings remain anecdotal. We performed single-nucleus amplicon sequencing of 39,800 neurons from the superior temporal gyrus of sporadic FTLD-TDP type C patients (34,738 neurons, 52 individuals) and non-demented controls (5,062 neurons, 26 individuals) using the Mission Bio Tapestri platform and investigated somatic variants in TARDBP and other FTLD-TDP-associated genes in a case-control setting. We uncovered an extensive landscape of ultra-low-frequency (<1%) somatic mutations across all analysed genes, including TARDBP . Rare somatic occurrences of known ALS/FTD-associated germline TARDBP variants, including p.N267S and p.M337V, were identified exclusively in patients. Among all targeted genes, TARDBP had the highest proportion of neurons harbouring a somatic variant, and this mutational burden was lower in individuals who died at an older age. Strikingly, the C-terminal domain of TDP-43, where most ALS/FTD germline pathogenic variants reside, exhibited a lower neuronal mutational burden than its other domains. This suggests that neurons harbouring damaging mutations may undergo progressive loss prior to autopsy, leaving only rare survivors at frequencies too low to detect by bulk or small-scale single-cell approaches. Together, our findings provide an unprecedented resolution into the somatic mutational landscape of post-mitotic neurons in FTLD-TDP type C and reveal a gene-specific layer of neuronal mosaicism that current single-cell WGS studies fail to detect.
Ultrasound-guided surgery in musculoskeletal care: a framework for responsible integration
Lavigne, Alexandre , Boettcher, Brennan J. , Khadavi, Michael , Nazarian, Levon N. , Marès, Olivier, Omodani, Toru , Sussman, Walter I, Marès, Olivier , Boudier‐Revéret, Mathieu , Sussman, Walter I.

Mayo Clinic

British Journal of Sports Medicine | September 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: bjsports-2026-112612

10.1136/bjsports-2026-112612 | PMID 42754378 Get It

Inflammation in coronary syndromes in clinical practice: a clinical consensus statement of the Association for Acute Cardiovascular Care of the European Society of Cardiology, the European Society of Cardiology Working Group on Myocardial and Pericardial D
Kharlamov, John Alexander, Lenz, Max , Madonna, Rosalinda, Schaubroeck, Hannah, Morosin, Marco , Wojta, Johann , Evans, Paul, Huber, Kurt , Tarkin, Jason, Tsaban, Gal , Roubille, François , Lenz, Max , Wojta, Johann , Kerneis, Mathieu , Lazaros, George , Huber, Kurt , Hassager, Christian , Heymans, Stephane , Tsaban, Gal , Imazio, Massimo , Sionis, Alessandro , Kharlamov, Alexander , Madonna, Rosalinda , Delmas, Clément , Schaubroeck, Hannah , Vandenbriele, Christophe , Evans, Paul , Hassager, Christian , Tarkin, Jason M. , Heymans, Stéphane , Christodorescu, Ruxandra , Imazio, Massimo , Sionís, Alessandro

Mayo Clinic

European Heart Journal: Acute Cardiovascular Care | July 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ehjacc/zuag086 | PMID 42536391 Get It

Abstract Inflammation is a key driver of coronary syndromes across the continuum from chronic coronary syndromes to acute coronary syndromes. It contributes to atherogenesis, plaque destabilization, and ischaemic events and influences myocardial injury, repair, and remodelling. Inflammatory activity is further amplified by metabolic and autoimmune comorbidities such as diabetes, obesity, and connective tissue diseases, with obesity representing a major driver of chronic low-grade inflammation through adipose tissue dysfunction and cytokine activation, while psychosocial stress and environmental exposures including air pollution serve as additional triggers. Genetic variations, including human leucocyte antigen genotypes, modulate individual susceptibility to vascular inflammation and myocardial injury. This expert consensus from the European Society of Cardiology’s Association for Acute CardioVascular Care summarizes the current understanding of inflammation across the full spectrum of coronary syndromes, including underlying mechanisms, relevant biomarkers, and imaging approaches that characterize vascular inflammation, and integrates insights from experimental and clinical studies. Importantly, this document provides explicit consensus-based guidance on when, how, and in whom inflammation should be assessed and treated in routine clinical practice. While the causal association between inflammation and atherosclerotic cardiovascular disease is well established, pharmacological modification of inflammation has produced conflicting evidence. Some agents, such as low-dose colchicine, have demonstrated modest reductions in cardiovascular events, although results across trials have been inconsistent. Other anti-inflammatory therapies have not shown clinical benefit, whereas selective cytokine inhibition with canakinumab has reduced cardiovascular risk at the cost of increased infection rates. The present manuscript also focuses on the evaluation of inflammatory activity in cardiovascular patients in routine clinical practice. It further discusses criteria for patient selection and clinical decision-making regarding the introduction of anti-inflammatory therapy in individuals with established atherosclerotic cardiovascular disease.
Learning Curves and Complexity Evolution in Robotic Liver Surgery
Kuemmerli, Christoph , Hess, Gabriel Fridolin , Billeter, Adrian T. , Benedetto, Fabrizio Di , Odorizzi, Roberta, Sucandy, Iswanto , Aegerter, Noa L. E., Berchtold, Caroline , Bernardi, L. , Cristaudi, Alessandra , Balzano, E , Koh, Ye-Xin, Lin, Charles Chung-Wei, Fukumori, Daisuke , Tschuor, Christoph , White, Steve, Kroge, P Von, Heumann, Asmus , Meyere, Céline De, D’hondt, M, Haak, Fabian, Stättner, Stefan, Primavesi, Florian, Morgül, Haluk , Andreou, A, Ratti, F, Esquer, Ignacio Sánchez, Robles-Campos, Ricardo, Lopez-Lopez, Victor, Wakabayashi, Go , Nebbia, Martina, Rahbari, Nuh N., Ferretti, Stefano, Ettore, Giuseppe , Croner, RS , Dong, Y, Starlinger, P, Nickel, F, Müller, Beat P., Hess, Gabriel F , Guidetti, Cristiano , di Benedetto, Fabrizio , Sucandy, Iswanto , Aegerter, Noa L E , Berchtold, Caroline , Bernardi, Lorenzo , Cristaudi, Alessandra , Balzano, Emanuele , Ghinolfi, Davide , Goh, Brian K P , Fukumori, Daisuke , Tschuor, Christoph , Pandanaboyana, Sanjay , De Meyere, Celine , Seehofer, Daniel , Esquer, Ignacio Sánchez , Müller, Philip C , Koh, Ye-Xin , Lin, Charles Chung-Wei, Tschuor, Christoph , Kroge, Philipp H. von , D’Hondt, Mathieu , Haak, Fabian , Stättner, Stefan , Primavesi, Florian , Ratti, Francesca , Robles-Campos, Ricardo, López‐López, Víctor , Wakabayashi, Taiga , Nebbia, Martina , Gilg, Stefan , Birgin, Emrullah , Ferretti, Stefano , Ettore, Giuseppe Maria, Rahimli, Mirhasan , Nickel, Felix , Müller-Stich, Beat Peter

Mayo Clinic

Annals of Surgery | June 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000007123 | PMID 42307103 Get It

Objective: To evaluate the institutional learning curve of robotic liver resection (RLR), its association with surgical complexity and outcomes in an international multicenter cohort. Summary of Background Data: RLR is increasingly adopted worldwide, but the dynamics of the learning process and its impact on surgical outcomes remain poorly defined. Methods: This international, multicenter, retrospective cohort study included consecutive patients who underwent RLR between 06/2013 and 12/2024 across 22 expert centers. Based on the first 150 cases at each center, three phases were used to define the learning curve: operative time for competency, major complications for proficiency, and textbook outcome for mastery. Risk-adjusted generalized additive models were used to assess the learning process. Benchmark performance was compared to international reference values. Results: Among 2,331 patients, the most common indications were hepatocellular carcinoma (36%), benign lesions (23%) and colorectal liver metastases (21%). Operative time decreased after achieving competency (case #62), from 240 to 220 minutes ( P <0.001). Major morbidity reached a plateau during the proficiency phase (cases #63–138; 9% vs. 11%, P =0.144), while progression to mastery (cases #139–150) was associated with a higher rate of textbook outcome (76% vs. 87%, P =0.021). In contrast, conversion (5.1% vs. 4.9% vs. 2%), bile leak (4.0% vs. 5.3% vs. 3.8%), and 90-day mortality (0.7% vs. 0.9% vs. 0.9%) remained low and stable across all learning phases. Importantly, benchmark criteria for operative time, hospital stay, and textbook outcome were met across all complexity groups, including during the early learning phase. Conclusions: Robotic liver surgery shows progressive outcome improvement with early achievement of benchmark-level results and stable performance across increasing complexity. These findings indicate that, in experienced centers, RLR can be safely implemented and integrated into clinical practice, supporting its key role in modern hepatobiliary surgery.
Volume-Staged Stereotactic Radiosurgery in Pediatric Patients With Large Brain Arteriovenous Malformations: An International, Multicenter Study
Hajikarimloo, Bardia , Tos, Salem M., Ferguson, Robert , Chan, Jason W., Sneed, Penny K. , McDermott, Michael W., Seymour, Zachary , Grills, Inga, Reda, Wael A., Tawadros, Sameh R., Abdelkarim, Khaled, Emad, Reem M. , Lunsford, L. Dade, Niranjan, Ajay, Peker, S A, Samanci, Yavuz, Lee, Cheng-chia, Yang, Huai-che, Sheehan, Darrah, Sheehan, Kimball, Liscak, Roman, Chytka, Tomáš , Alzate, Juan, Kondziolka, Douglas, Moreno, Nuria Martínez , Álvarez, Roberto Martínez , Hallan, David R , Fritch, Chanju, Jareczek, Francis J., Sciscent, Bao Y., Mathieu, David, Carrier, Louis, Abdelsalam, Ahmed, Starke, Robert M., BENJAMIN, CAROLINA, Almeida, Timoteo, Singh, S.P., Lazo, Erwin, Chen, C Y, Esquenazi, Yoshua, Becerril-Gaitan, Andrea, Blanco, Angel I., Palmer, Joshua D., Picozzi, Piero, Lanterna, Luigi Alberto Andrea, Bowden, Greg N., Peterson, Jennifer L., Chiang, Veronica , Pikis, Stylianos , Sheehan, Jason P. , Sheehan, Jason , Tos, Salem M , Mantziaris, Georgios , Shinya, Yuki , Chan, Jason , McDermott, Michael W. , Nabeel, Ahmed M. , Reda, Wael A. , Tawadros, Sameh R. , El-Shehaby, Amr M. N. , Bin-Alamer, Othman , Lunsford, L. Dade , Niranjan, Ajay , Peker, Selçuk , Samancı, Yavuz , Lee, Cheng-chia, Yang, Huai‐Che , Sheehan, Darrah, Sheehan, Kimball , Liščák, Roman , Alzate, Juan Diego , Kondziolka, Douglas, Meng, Ying , Fritch, Chanju , Jareczek, Francis J. , Sciscent, Bao Y. , Mathieu, David , Abdelsalam, Ahmed , Starke, Robert M. , Almeida, Timóteo , Tripathi, Manjul , Speckter, Herwin , Lazo, Erwin , Esquenazi, Yoshua , Becerril‐Gaitan, Andrea , Amsbaugh, Mark J. , Upadhyay, Rituraj , Palmer, Joshua D. , Franzini, Andrea , Picozzi, Piero , Lanterna, Andrea Luigi, Bowden, Greg , Warnick, Ronald E.

Mayo Clinic

Neurosurgery | June 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/neu.0000000000004136 | PMID 42300133 Get It

BACKGROUND AND OBJECTIVES: Pediatric large-volume brain arteriovenous malformations (AVMs) carry a substantial lifelong hemorrhage risk, neurological symptoms, and treatment morbidity. Single-session stereotactic radiosurgery (SRS) is often unsuitable due to constraints on dose-volume toxicity. Volume-staged SRS (VS-SRS) enables sequential dosing of large nidus volumes, potentially enhancing safety while maintaining efficacy. Evidence in children remains limited. We aimed to evaluate outcomes of VS-SRS for large AVMs in pediatric patients. METHODS: A multicenter retrospective cohort was assembled from 21 centers, including patients aged younger than 21 years treated with VS-SRS for AVMs >10 cm 3 . Clinical and radiological end points included obliteration, hemorrhage, and permanent symptomatic radiation-induced changes (RIC). RESULTS: A total of 103 patients were included (median age 14 years; IQR, 12-17). The median nidus volume at first stage was 18.2 cm 3 (IQR, 12.3-25.6). Median prescription dose per stage was 17 Gy (IQR, 16-18). The median clinical follow-up from the first stage was 57.5 months (IQR, 25-138). Obliteration occurred in 42 of 103 patients (40.8%), with actuarial rates of 6.9% (95% CI: 2.8-14) at 3 years and 29% (95% CI: 20-39) at 5 years. Hemorrhage occurred in 17 of 103 patients (16.5%) during follow-up, and permanent RIC was observed in 9 of 103 patients (8.7%). CONCLUSION: VS-SRS is a reasonably safe, selected option for pediatric large-volume AVMs when microsurgical or endovascular cure is not feasible or prudent. Delivering ≥17 Gy per stage while limiting each treatment volume to <15 cm 3 supports durable nidus control with acceptable toxicity. VS-SRS represents a key modality in multidisciplinary management of this historically difficult-to-treat population.
Persistence to Botulinum Toxin and Factors Associated With Discontinuation: A Retrospective Cohort Study (P5-14.010)
Wainberg, Michael, Zhang, Jinming, Page, Simon, Bouchard, Jonathan, Mann, Amandeep, BENETEAU, Mathieu, Schultz, Billie, Zhang, Jinming , Page, Simon , Mann, Amandeep, Beneteau, Mathieu , Schultz, Billie A.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000216901 Get It

Efficacy and safety profile of volume-staged stereotactic radiosurgery for ruptured, large pediatric arteriovenous malformations: a multicenter cohort analysis
Tos, Salem M., Hajikarimloo, Bardia, Chan, Jason W., Sneed, Penny K. , McDermott, Michael W. , Seymour, Zachary , Grills, Inga, Reda, Wael A., Tawadros, Sameh R., Eldin, Reem Emad, Lunsford, L Dade, Niranjan, Ajay, Samanci, Yavuz, Lee, Cheng-chia, Yang, Huai-che, Sheehan, Darrah, Sheehan, Kimball, Liscak, Roman, Chytka, Tomáš , Alzate, Juan, Kondziolka, Douglas, Moreno, Nuria Martínez , Martínez‐Álvarez, Roberto , Hallan, David R , Fritch, Chanju, Jareczek, Francis, Sciscent, Bao Y., Mathieu, D, Carrier, Louis, Abdelsalam, Ahmed, Starke, Robert M., BENJAMIN, CAROLINA, Almeida, Timoteo, Singh, S.P., Lazo, Erwin, Chen, Ching-Jen, Esquenazi, Y., Becerril-Gaitan, Andrea, Blanco, Angel I., Palmer, Joshua D., Picozzi, Piero, Lanterna, Luigi Alberto Andrea, Bowden, Greg N., Peterson, Jennifer L., Chiang, Veronica , Pikis, Stylianos , Xu, Zhiyuan, Sheehan, Jason P., Shinya, Yuki , Tos, Salem M , Hajikarimloo, Bardia , Mantziaris, Georgios , Chan, Jason , Nabeel, Ahmed M. , Reda, Wael A. , Tawadros, Sameh R. , Abdelkarim, Khaled , El-Shehaby, Amr M. N. , Eldin, Reem M. Emad, Bin-Alamer, Othman , Lunsford, L. Dade , Niranjan, Ajay , Peker, Selçuk , Samancı, Yavuz , Lee, Cheng-chia, Yang, Huai‐Che , Sheehan, Darrah, Sheehan, Kimball , Liščák, Roman , Alzate, Juan Diego , Meng, Ying , Martinez-Álvarez, Roberto, Fritch, Chanju , Jareczek, Francis J. , Sciscent, Bao Y. , Mathieu, David , Abdelsalam, Ahmed , Starke, Robert M., Almeida, Timóteo , Tripathi, Manjul , Speckter, Herwin , Lazo, Erwin , Esquenazi, Yoshua , Becerril‐Gaitan, Andrea , Amsbaugh, Mark J. , Upadhyay, Rituraj , Palmer, Joshua D. , Franzini, Andrea , Picozzi, Piero , Lanterna, Andrea Luigi, Bowden, Greg , Sheehan, Jason P.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | June 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-10

10.3171/2026.1.peds25593 | PMID 42284606 Get It

OBJECTIVE Ruptured, large pediatric arteriovenous malformations (AVMs) pose a significant management challenge due to high rerupture risk and the morbidity of conventional treatments. Volume-staged stereotactic radiosurgery (VS-SRS) has emerged as an alternative; however, evidence for its use in this specific population is limited. This study aimed to evaluate the long-term efficacy and safety of VS-SRS for ruptured, large AVMs in a dedicated pediatric cohort. METHODS This international, multicenter, retrospective cohort study from 21 centers analyzed outcomes for 42 pediatric patients (age < 18 years) with previously ruptured, large AVMs treated with VS-SRS. The primary outcome was complete AVM obliteration, and secondary outcomes included post-SRS hemorrhage, radiation-induced changes (RICs), and favorable outcome. Favorable outcome in this study was defined as obliteration without post-SRS hemorrhage or permanent RIC. RESULTS At the initial SRS, the median patient age was 14.5 years, and the median AVM volume was 15.0 cm 3 ; most AVMs were high grade (Spetzler-Martin grades IV and V). With a median follow-up of 41.5 months, complete AVM obliteration was achieved in 21 patients (50.0%). The cumulative obliteration rate was 37% at 5 years and 56% at 10 years. Patients with a nidus volume of ≤ 10 cm 3 had significantly higher cumulative obliteration rates than those with a nidus volume > 10 cm 3 (log-rank test, p = 0.021). Similarly, patients treated with a prescription dose > 17 Gy showed significantly higher cumulative obliteration rates compared to those treated with a dose ≤ 17 Gy (log-rank test, p = 0.012). The cumulative 5-year incidences of hemorrhage and RICs following VS-SRS were 19% and 7%, respectively. In multivariable analysis, only larger total AVM volume was an independent predictor of a lower likelihood of favorable outcome (hazard ratio 0.89, 95% CI 0.80–0.99; p = 0.036). CONCLUSIONS In this multicenter pediatric cohort, VS-SRS for ruptured, large AVMs provides a reasonable chance of long-term obliteration, but generally acceptable risks of post-SRS hemorrhage and RICs exist. VS-SRS should be considered as an option for pediatric patients with large, ruptured AVMs.
Safety of esophageal endoscopic submucosal dissection of Barrett’s esophageal neoplasia: an analysis of factors associated with stricture formation
Omae, M, Isacsson, N Hentati, Maltzman, H, Mathieu, P, Moll, F, Bourke, M J, Gupta, S, Ebigbo, A, Roser, D A, Deprez, P, Maximilien, B, Wang, K K, Leggett, C L, Koch, A D, Maan, AD I, Baldaque-Silva, F, Omae, Masami , Isacsson, Nils Hentati , Maltzman, Henrik , Moll, Frederic C., Bourke, Michael J. , Ebigbo, Alanna , Barret, Maximilien , Leggett, Cadman L. , Baldaque‐Silva, Francisco

Mayo Clinic

Endoscopy | June 5, 2026 | Volume: 58 | Issue: S 03 | Pages: S107-S108

10.1055/s-0046-1820814 Get It

Clinical Practice of Indocyanine Green Fluorescence Imaging in Robotic Liver Surgery – A Global Expert Survey
Aegerter, N L E, Kuemmerli, C, Billeter, A T, Berchtold, C, Nickel, F, Guidetti, C, Wakabayashi, T, Sucandy, I, Goh, B K, D’hondt, M, Marques, H Pinto, Eden, J, Dutkowski, P, Hawksworth, J, Starlinger, P, Müller, B P, Müller, P C, Aegerter, Noa L E , Kuemmerli, Christoph , Billeter, Adrian T. , Berchtold, Caroline , Nickel, Felix , Guidetti, Cristiano , Sucandy, Iswanto , Goh, Brian K P , D’Hondt, Mathieu , Eden, Janina , Dutkowski, Philipp , Hawksworth, Jason Solomon , Müller, P C

Mayo Clinic

British Journal of Surgery | June 3, 2026 | Volume: 113 | Issue: Supplement_5 | Pages: No page available

10.1093/bjs/znag055.029 Get It

Abstract Background Indocyanine green (ICG) fluorescence imaging is increasingly incorporated into robotic liver resections (RLR), yet clinical practice regarding timing, dosage, and staining techniques is divergent. Aims This international expert survey aimed to characterize current practices for ICG in RLR. Methods Experts in RLR were invited to participate based on surgical volume (experience of 50 RLR and 30 annual RLR). A 74-item questionnaire was developed following a literature search and reviewed by a steering committee. The survey addressed indications, timing, dosage, imaging technology, benefits, limitations, training, and future directions of ICG use. Responses collected between September and October 2025 were analyzed. Results Seventy experts from 19 countries completed the survey, corresponding to an 88% response rate. Centers performed a median of 180 annual liver resections, including 55 RLR. Most experts used ICG (96%) during RLR. Anatomical demarcation (91%), tumor localization (60%), and biliary anatomy assessment (60%) were the most frequent indications. 60% of experts use preoperative ICG, while intraoperative ICG is mainly administered for demarcation (67%) and biliary tract visualization (40%). Considerable heterogeneity exists in dosage, timing, and staining techniques, particularly in cirrhotic livers and for tumor localization. Only half of the experts had standard operating procedures, whereas 64% expressed the need for a higher degree of standardization. Reported benefits of ICG use included improved anatomical orientation, margin assessment, lesion detection, and support during complex resections. Perceived limitations included background fluorescence, tissue penetration and variable staining in diseased parenchyma. 80% anticipated improved outcomes with combined ICG and three-dimensional image-guidance. Conclusion ICG fluorescence is widely used in RLR and is an important cornerstone for precision-guided robotic liver surgery. Standardized clinical practice guidelines, structured training, and technological improvements in imaging and navigation systems are claimed to optimize its clinical use.